Pre-made Ivuxolimab benchmark antibody ( Whole mAb, anti-TNFRSF4/CD134 therapeutic antibody, Anti-ACT35/IMD16/OX40/TXGP1L Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Ivuxolimab biosimilar, Whole mAb, Anti-TNFRSF4/CD134 Antibody: Anti-ACT35/IMD16/OX40/TXGP1L therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Ivuxolimab (also known as PF 4518600 or PF 8600) is an OX40 receptor agonist, as an intravenous therapy for solid tumours is in development with Pfizer.
| Products Name (INN Index) | Pre-Made Ivuxolimab biosimilar, Whole mAb, Anti-TNFRSF4/CD134 Antibody: Anti-ACT35/IMD16/OX40/TXGP1L therapeutic antibody |
|---|---|
| INN Name | Ivuxolimab |
| Target | TNFRSF4 |
| Format | Whole mAb |
| Derivation | NA |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Pfizer,Dana-Farber Cancer Institute,M. D. Anderson Cancer Center,National Cancer Institute USA,University of Southern California |
| Conditions Approved | NA |
| Conditions Active | Breast cancer,Renal cell carcinoma,Solid tumours,Acute myeloid leukaemia,Squamous cell cancer,Follicular lymphoma |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | TNFRSF4 |
| Package |
